Catalyst Wire Dossier Catalyst Wire Dossier

Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237)

Hydrocodone bitartrate extended-release · Teva Branded Pharmaceutical Products R&D, Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237), covering 2017-04-05 to 2017-06-05. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time [Phase 3]

See pricing